Halozyme Therapeutics Inc. (HALO)

17.04
NASDAQ : Health Technology
Prev Close 16.54
Day Low/High 16.45 / 17.05
52 Wk Low/High 13.24 / 21.48
Avg Volume 680.90K
Exchange NASDAQ
Shares Outstanding 144.56M
Market Cap 2.39B
EPS 0.50
P/E Ratio 45.94
Div & Yield N.A. (N.A)

Latest News

Halo Labs Provides Operational Update & Announces Closing Of Promissory Note

Halo Labs Provides Operational Update & Announces Closing Of Promissory Note

Halo Labs Inc. (" Halo" or the " Company") (NEO:HALO, OTC:AGEEF) is pleased to provide an operational update given the recent developments at the Company in the past few months and announces the closing of a promissory note financing.

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

- Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation

First Week Of HALO February 15th Options Trading

First Week Of HALO February 15th Options Trading

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Halozyme Therapeutics, Inc. - HALO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Halozyme Therapeutics, Inc. - HALO

NEW YORK, Nov. 29, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc.

Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival

Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival

-FDA Agrees to Company Request to Change Primary Endpoint to Overall Survival-

Halozyme Reports Third Quarter 2018 Financial Results

Halozyme Reports Third Quarter 2018 Financial Results

- ENHANZE® Licensed to Roche for up to Three Additional Targets, Includes $25 Million Upfront Payment, Plus the Potential for Future Milestone and Royalty Payments -

Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications

Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications

SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties

Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Oct. 30, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress

Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress

SAN DIEGO, Oct. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme To Host Third Quarter 2018 Financial Results Conference Call

Halozyme To Host Third Quarter 2018 Financial Results Conference Call

SAN DIEGO, Oct. 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment

Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment

- In animal models PEGPH20 increased vascular volume and perfusion, decreased hypoxia and depleted an important proangiogenic growth factor VEGF-A165 through hyaluronan degradation -

Halozyme Therapeutics To Participate In Upcoming Investor Conference

Halozyme Therapeutics To Participate In Upcoming Investor Conference

SAN DIEGO, Sept. 20, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada

SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Appoints Bernadette Connaughton To Board Of Directors

Halozyme Appoints Bernadette Connaughton To Board Of Directors

SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Names Benjamin Hickey As Chief Commercial Officer

Halozyme Names Benjamin Hickey As Chief Commercial Officer

SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Therapeutics To Participate In Upcoming Investor Conferences

Halozyme Therapeutics To Participate In Upcoming Investor Conferences

SAN DIEGO, Aug. 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

First Week Of March 2019 Options Trading For Halozyme Therapeutics (HALO)

First Week Of March 2019 Options Trading For Halozyme Therapeutics (HALO)

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the March 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATAX, COR, GPRK, KWR, NYLD Downgrades: CKH, CUTR, CYD, DRQ, EDAP, FLXS, GOLD, HALO, HDB, IRDM, KND, MSCC, XRX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, ATRC, BKE, CRSP, HALO Downgrades: GIFI, GTE, MGI, NNI, RBBN, SHAK, SPPI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

Halozyme Therapeutics Stock Sees Short Interest Decrease By 12%

The most recent short interest data has been released for the 01/31/2018 settlement date, which shows a 1,401,809 share decrease in total short interest for Halozyme Therapeutics Inc , to 10,232,867, a decrease of 12.05% since 01/12/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Halozyme Therapeutics Reaches Analyst Target Price

Halozyme Therapeutics Reaches Analyst Target Price

In recent trading, shares of Halozyme Therapeutics Inc have crossed above the average analyst 12-month target price of $20.11, changing hands for $20.36/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Roku, Sierra Wireless, Visa, Cimarex Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Roku, Sierra Wireless, Visa, Cimarex Energy, First Solar, Halozyme Therapeutics.

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Good Things Come to Those Who Buy: Cramer's 'Mad Money' Recap (Monday 12/18/17)

Don't buy big here and don't buy all at once, but it's not too late to ride this bull to profits, says Jim Cramer.

TheStreet Quant Rating: C (Hold)